A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback

Simply Wall St.11-16

Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583892665?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-16 11:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583892665","market":"nz","top_or_hot":-1,"title":"A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback","media":"Simply Wall St.","content":"<div>\n<p>Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look at Biohaven’s Valuation Following $175 Million Share Offering and Recent FDA Setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-16 11:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of","article_id":"2583892665","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bhvn/biohaven/news/a-look-at-biohavens-valuation-following-175-million-share-of","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2583892665","pubTimestamp":1763263761,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s balance sheet after recent challenges.\nSee our latest analysis for Biohaven.\nBiohaven’s recent stock performance has been dominated by sharp moves, most notably a roughly 48% drop in the last three months after the FDA declined to approve its experimental drug. This led to a follow-on stock...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Biohaven在发行1.75亿美元股票和最近FDA挫折后的估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":1},"content_text":"Biohaven (NYSE:BHVN) just completed a $175 million follow-on public offering, issuing new shares at $7.50, which is lower than its prior trading price. This move is aimed at bolstering the company’s balance sheet after recent challenges. See our latest analysis for Biohaven. Biohaven’s recent stock performance has been dominated by sharp moves, most notably a roughly 48% drop in the last three months after the FDA declined to approve its experimental drug. This led to a follow-on stock offering at a sizable discount. The 1-year total shareholder return now stands at -81%, reflecting both operational setbacks and ongoing market uncertainty. However, the latest $175 million cash infusion signals the company is working to regain its footing for the long term. If you’re tracking how biotech pivots can shape near-term returns, it’s also a perfect moment to discover See the full list for free. With Biohaven’s shares battered and new funding in hand, the crucial question for investors is whether the current price reflects just the recent setbacks or also factors in all future risks and recovery potential. This leaves room for a true buying opportunity, or the market may have already priced in everything ahead. AdvertisementPrice-to-Book of -64.2x: Is it justified? Biohaven’s price-to-book ratio is -64.2x, which stands out starkly when benchmarked against both the biotech industry and peer averages and highlights concerns over fundamentals. The price-to-book ratio shows how the market values a company’s net assets. For companies like Biohaven, where liabilities exceed assets and equity is negative, this measure turns negative and reflects a distressed balance sheet rather than hidden value. Compared to the US Biotechs industry average of 2.5x and a peer average of 14x, Biohaven’s negative ratio signals that the market sees significant risk in its current financial profile. In these cases, traditional valuation signals may not apply and investors should be highly cautious interpreting a negative book value as a potential “bargain.” See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of -64.2x (ABOUT RIGHT) However, operational losses and a volatile share price still pose significant risks. These factors could disrupt any anticipated turnaround for Biohaven in the coming quarters. Find out about the key risks to this Biohaven narrative.  Build Your Own Biohaven Narrative If you’d like to dig into the details and piece together your own story from the numbers, you can build your own take in just a few minutes. Do it your way A great starting point for your Biohaven research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision. Looking for more investment ideas? Smart investors keep their radar up for new opportunities. Don’t let the next winner pass you by simply because you stayed focused on a single pick.  Unlock high potential with these 24 AI penny stocks as you tap into the AI wave and back tomorrow’s game-changing disruptors. Capture income growth by checking out these 16 dividend stocks with yields > 3%, which spotlights stocks known for consistent returns and attractive yields. Seize early-stage momentum by targeting these 3584 penny stocks with strong financials that are poised for breakout performance in dynamic markets.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Biohaven might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583892665","isCrawlerRequest":true}